NOTA Labs

NOTA Labs is an early-stage biotech leveraging nitric oxide's broad therapeutic properties—antimicrobial, antiviral, anti-inflammatory, and anti-thrombotic—through two core platform technologies: the NOGEN electrochemical system for high-volume gas delivery and the LANOR UV-LED system for compact, localized generation. The company's pipeline addresses significant unmet needs in hospital-acquired infections (catheter lock solutions), neonatal care (PPHN), cardiac surgery, and chronic respiratory diseases. Backed by NIH SBIR funding, NOTA is positioned to advance its pre-clinical programs toward clinical validation in high-value medical markets.

Two core platforms for nitric oxide (NO) delivery: 1) NOGEN, an electrochemical system for on-demand, high-volume NO gas generation for inhalation. 2) LANOR, a UV-LED based system that uses light to release NO from a solid donor molecule for localized/portable delivery.

NOTA competes with established inhaled NO cylinder systems in neonatal care and potential developers of next-generation NO delivery devices. For catheter locks, it faces competition from existing antibiotic and anticoagulant solutions. Its competitive edge lies in its novel, potentially safer and more controllable delivery mechanisms.